title: Pasteurization of bone for tumour eradication prior to reimplantation - an in vitro & pre-clinical efficacy study.
abstract: OBJECTIVE
  In current era of limb-salvage therapy, pasteurization of bone sarcomas is receiving growing attention as a potential extracorporeal treatment and cost-effective alternative to allografts and radiation before surgical reimplantation. Detailed in vitro and in vivo pre-clinical study to evaluate efficacy of pasteurization to eradicate malignant cells has not been reported yet. The present study was carried out to assess the efficacy of pasteurization to kill tumour cells both in vitro and in vivo.
  
  
  METHODS
  Surgically resected specimens of osteosarcomas (n=4) were cut into equal halves and one section was pasteurized by heating at 60°C to 65°C for 40 min. Paired samples before and after pasteurization were studied in vitro for DNA ploidy, evaluation of histological change and elimination of mitotic activity. These tissues were transplanted in immune-deficient NOD-SCID mice to evaluate effect on tumour-generating ability, presence of human nuclei, osteopontin and cytokine/chemokines released in tumour-transplanted mice.
  
  
  RESULTS
  Non-pasteurized tumour samples had viable tumour cells which exhibited significant growth in culture, increased proliferative ability and clonogenic potential while respective pasteurized tumour tissues did not grow in culture and did not exhibit clonogenicity. Flow cytometry revealed that propidium iodide positive dead cells increased significantly (P< 0.01) post pasteurization. Seven of 12 non-pasteurized tumour transplanted mice demonstrated tumour-forming ability as against 0 of 12 in pasteurized tumour transplanted mice. Solid tumour xenografts exhibited strong expression of anti-human nuclei and osteopontin by immunohistochemistry as well as secretary human interluekin-6 (IL-6) while pasteurized mice failed to express these markers.
  
  
  CONCLUSIONS
  This study has provided a basis to establish pasteurization as being efficacious in ensuring tumour eradication from resected bone tumour specimens. Pasteurized tumour bearing bone can thus safely be used to reconstruct large defects after tumour resection.
authors.forename: Jyoti
authors.initials: J
authors.lastname: Kode
authors.forename: Prasad
authors.initials: P
authors.lastname: Taur
authors.forename: Ashish
authors.initials: A
authors.lastname: Gulia
authors.forename: Nirmala
authors.initials: N
authors.lastname: Jambhekar
authors.forename: Manish
authors.initials: M
authors.lastname: Agarwal
authors.affiliation: Department of Orthopedic Oncology, Tata Memorial Hospital, Mumbai, India.
authors.forename: Ajay
authors.initials: A
authors.lastname: Puri
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000628:therapy*; D001842:Bone and Bones / Q000166:cytology* / Q000601:surgery; D002470:Cell Survival / Q000502:physiology; D016207:Cytokines / Q000378:metabolism; D005434:Flow Cytometry; D006358:Hot Temperature; D006801:Humans; D007150:Immunohistochemistry; D007194:India; D023821:Limb Salvage / Q000379:methods*; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D053495:Osteopontin / Q000378:metabolism; D012516:Osteosarcoma / Q000628:therapy*; D060888:Real-Time Polymerase Chain Reaction; D013242:Sterilization / Q000379:methods*
chemical_list: D016207:Cytokines; D053495:Osteopontin